Antibodies against claudin 18.2 for cancer diagnosis
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ASTELLAS PHARMA INC
- Publication Date
- 2022-02-25
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201380024247.0. The original application is the PCT international application PCT / EP2013 / 001331 filed on May 6, 2013, which entered the Chinese national phase on November 7, 2014. technical field
[0002] The present invention relates to antibodies against claudin 18.2 for use in cancer diagnosis. Background technique
[0003] Claudin is an integral membrane protein located within the tight junction of epithelium and endothelium. Claudin is predicted to have four transmembrane segments, with two extracellular loops, and both N- and C-termini located in the cytoplasm. The claudin (CLDN) family of transmembrane proteins plays a key role in the maintenance of epithelial-endothelial tight junctions and may also play a role in the maintenance of the cytoskeleton and in cell signal transduction.
[0004] The claudin 18 (CLDN18) molecule is an integrated transmembrane prot...